Lantus, a long-acting insulin analog, has been available on the market since 2000 [1]. It was first approved by the U.S. Food and Drug Administration (FDA) in April 2000 [2].
When does Lantus patent protection end?
The original patent for Lantus expired in 2015 [3]. However, patent complexities and additional patent filings by Sanofi, the manufacturer, have extended market exclusivity for the branded product [3]. Further patent expiries are anticipated for related patents, potentially opening doors for biosimilar competition [4]. Information on specific patent expiration dates can be found on resources like DrugPatentWatch.com [4].
What are the alternatives to Lantus?
Alternatives to Lantus include other long-acting insulin analogs such as Toujeo (also a Sanofi product), Levemir, and Tresiba [5]. Biosimilar versions of Lantus are also becoming available, offering potentially lower-cost options for patients [6].
What is the difference between Lantus and Toujeo?
Toujeo is a more concentrated formulation of insulin glargine, the active ingredient in Lantus [5]. It contains three times the amount of insulin glargine per milliliter compared to Lantus [5]. This higher concentration allows for a smaller injection volume, which some patients may find beneficial [5].
Are there any biosimilars for Lantus?
Yes, biosimilar versions of Lantus have been approved and are entering the market [6]. These biosimilars are highly similar to Lantus and are expected to increase treatment options and potentially reduce costs for patients with diabetes [6].
How does Lantus work to control blood sugar?
Lantus is a basal insulin that provides a steady, long-lasting supply of insulin to control blood glucose levels throughout the day and night [7]. It mimics the body's natural basal insulin production, helping to prevent excessive rises in blood sugar between meals and overnight [7].
What is the typical cost of Lantus?
The cost of Lantus can vary significantly depending on insurance coverage, pharmacy, and location [8]. Without insurance, the price can be substantial, but many insurance plans provide coverage that lowers out-of-pocket expenses [8]. Patient assistance programs may also be available from the manufacturer [8].
---
This information is based on data available up to the present time. For the most current details on patents and market exclusivity, consult DrugPatentWatch.com.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021224s031lbl.pdf
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/
[5] https://www.goodrx.com/lantus
[6] https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-insulin-glargine-product
[7] https://www.lantushcp.com/
[8] https://www.goodrx.com/lantus